Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.

scientific article published on August 2010

Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1600-0463.2010.02631.X
P698PubMed publication ID20666740

P50authorUlrik LassenQ39700481
Michael R. HorsmanQ47792821
Jesper Grau EriksenQ57064572
P2093author name stringIb Jarle Christensen
Marie-Thérése Stockhausen
Hans Skovgaard Poulsen
Helle Broholm
Kirsten Grunnet
Benedikte Hasselbalch
P2860cites workThe Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated MacrophagesQ28143066
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.Q34693504
Association of tumour vasculature with tumour progression and overall survival of patients with non-early gastric carcinomasQ36116036
A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain.Q40020748
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinibQ43742602
P433issue8
P921main subjecthypoxiaQ105688
glioblastomaQ282142
biomarkerQ864574
bevacizumabQ413299
cetuximabQ420296
P304page(s)585-594
P577publication date2010-08-01
P1433published inActa Pathologica et Microbiologica ScandinavicaQ15756643
P1476titleProspective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan
P478volume118

Reverse relations

cites work (P2860)
Q36103026A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma
Q37916313Angiogenesis in cancer. Basic mechanisms and therapeutic advances
Q34523319Antiangiogenic therapy for glioblastoma: current status and future prospects
Q36695514Assessing Current Therapeutic Approaches to Decode Potential Resistance Mechanisms in Glioblastomas
Q37954013Biomarkers predicting tumor response and evasion to anti-angiogenic therapy
Q39269316Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27KIP1 and MMP3 expression
Q27024235Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer
Q36103551Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas
Q40051006Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma
Q38298124Incorporation of biomarkers in phase II studies of recurrent glioblastoma
Q35779256Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
Q35895174Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
Q37856125Molecular Predictors of Response to Antiangiogenesis Therapies
Q48299999Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.
Q38021521Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions
Q35911350Personalized therapy in endometrial cancer: Challenges and opportunities
Q37955405Recurrent Glioblastoma: A Fresh Look at Current Therapies and Emerging Novel Approaches
Q48858178Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
Q34293163The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
Q36339837Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
Q36713503Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme

Search more.